This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Acadia Pharma, Sarepta Therapeutics: How to Trade Into Trial Results

NEW YORK ( TheStreet) -- The most common way to trade biotech run-ups is to find a stock with an upcoming FDA drug approval. Having an exact date provides run-up traders with a tight timeline to exit a trade before FDA makes it decision public. It's also possible to use the biotech run-up strategy to trade in stocks with pending clinical trial results.

The key to trading around a clinical trial is to only choose stocks where management has given a narrow timelines for the release of data. This does limit run-up trading opportunities because many companies prefer to be rather vague about predicting the completion of clinical trials. Trying to execute a profitable run-up trade in a stock with a clinical trial expected to report top-line results in the "second half of the year" or even the "fourth quarter" is just too risky.

Fear not, you can find run-up trading opportunities in clinical trial stocks if you look hard enough. Two upcoming examples: Acadia Pharmaceuticals (ACAD) and Sarepta Therapeutics (SRPT).

On Sept. 5, Acadia announced the completion of patient enrollment in a phase III study of pimavanserin as a treatment for Parkinson's disease psychosis. Included in Acadia's press release on that day was a gift to all acolytes of the BioRunUp trading strategy:

"Top-line results from this trial are expected to be announced by the end of November 2012."

Thank you!

Acadia's pimavanserin phase III study is very much a binary event for the company and will have a dramatic impact on the stock price. Acadia shares could easily double to $5 or more on positive results; likewise, the stock could fall below $1 per share if pimavanserin fails. Acadia closed Tuesday at $2.21.

The stock has already made a 50%-plus move since early June but I believe it will continue to run higher as we get closer to November and the anticipated release of the pimavanserin data. That's where run-up traders like myself will try to make money, but remember, we never hold through catalysts so the time to exit the trade is early or mid-November.

A lot has been written about Sarepta and the excitement over its experimental muscular dystrophy drug eteplirsen. The next big event for the stock is the presentation of updated data from a phase II study, scheduled for the World Muscle Society meeting on Oct. 13.

Sarepta shares have ripped from $4 to $16 this summer before retracing to $13 so far in September. I expect the hype and attention to pick up again as the data presentation nears. Run-up traders have an opportunity to capitalize on this hype by buying Sarepta shares as we get closer to the eteplirsen data release. Remember to sell before the data are released.

Catalyst Pharmaceutical Partners (CPRX) is a good demonstration of a successful BioRunUp trade executed around a clinical trial. On July 12, Catalyst updated investors about a phase II clinical trial involving an experimental therapy for cocaine addiction. The company guided to the release of trial results "around the end of September."

Catalyst shares were at 78 cents on July 12. One month later, the stock doubled in value. Catalyst closed Tuesday at $1.99. All in, that's a run up of 155% fueled mostly on anticipation of results from the company's phase II study.

Disclosure: No positions in any stocks mentioned.

Subscribe to Messier's biotech stock-trading service BioRunUp.com

Mark Messier is the founder of BioRunUp.com. Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In April 2010, Messier founded the subscription-based stock-trading web site BioRunUp.com to share his biotech trading ideas with the online investor community.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,073.21 +1.99 0.01%
S&P 500 1,976.33 -1.47 -0.07%
NASDAQ 4,504.7920 -1.06 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs